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the current review based on the transplant population:
What are the complete set of reasons patients known to be
at higher risk do not proceed to transplant? How many
patients attain a remission though relapse early and before
a donor is prepared? What role might persistence of
minimal residual disease have in the outcome of the cho-
sen treatments?
Thus, Warlick et al. provide important information for the
current issue of optimizing our timing of transplantation,
noting that with current standard induction therapy, there is
beneﬁt in either situation of early or delayed transplant,
conﬁrming an adage made popular by Willie Nelson, “The
early bird gets the worm, but the second mouse gets the
cheese.” Of course, as therapies evolve away from traditional
approaches, we will need to continually reassess the value of
consolidation after less intense or targeted therapies as well,
ensuring repeated analyses of this type should be considered
in the future.Financial disclosure: See Acknowledgments on page 147.
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there may be disease-speciﬁc differences, conditioning-
speciﬁc differences, or infection-related differences. On
this background we try to interpret each new provocativeWe have made undeniable progress in the application
of hematopoietic stem cell transplantation (HSCT) to a
variety of malignant and nonmalignant diseases. Patients
are older and have more comorbidities, most problems
with HLA compatibility are manageable, and supportive
care techniques have made the management of infections,
veno-occlusive disease, and other transplant-related tox-
icities much more tractable. And yet, improving the pre-
vention and treatment of graft-versus-host disease (GVHD)
remains a challenge. No wonder that any apparent inno-
vation that appears to be effective generates a great deal of
interest.
Our ﬁeld is littered with phase II studies of “promising”
agents and approaches that have failed to live up to their
promise in phase III studies [1-3]. A substantial problem
that we have dealt with poorly is the substantial hetero-
geneity of the patients to whom these innovations are
applied. Children may not respond the same way as adults;
GVHD after umbilical cord blood transplantation may bestudy.
There are a number of important caveats in analyzing
data involving patients with severe GVHD. With severe
GVHD of the gastrointestinal tract and complete loss of the
absorptive epithelium, even in the context of a perfectly
effective immunosuppressive therapy, at what pace do we
anticipate clinical improvement? Three days? One week?
One month? If the diarrhea improves in a few days, do we
ascribe beneﬁt to the new agent or was it a late response to
the previous therapy? The liver is even more problematic.
Few of us would advocate serial liver biopsies to assess the
response to an investigational therapy. With biopsy-proven
loss of biliary canaliculi, at what pace do we anticipate
normalization of the bilirubin? What if the bilirubin never
normalizes? Does that mean there is ongoing inﬂammation
or does it mean there is irreversible injury to small biliary
radicles?
The deﬁnition of steroid-refractory is critical as well. If we
decide after 3 days of methylprednisolone that steroids have
failed and enroll the patient in a phase II trial of a novel
agent, how do we interpret responses that occur in the next
week or even 2 weeks? Is this just the normal time course of
response to the initial therapy, that is, the time it takes for the
mucosa to regenerate, or is it a true response to the drug?
I suspect that many “promising” drugs fail in phase III trials
because the interpretation of response data was overly
optimistic.
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the piling on of additional immunosuppressants may tran-
siently improve organ function, but prolonged immunologic
failure results in deaths from infection. Two therapies seem
to provide some degree of GVHD control without increasing
global, nonspeciﬁc immunoincompetence: extracorporeal
photopheresis (ECP) [4,5] and mesenchymal stem cell (MSC)
therapy.
In this issue of Blood and Bone Marrow Transplantation,
Kurtzberg and colleagues [6] present a multicenter, phase II
trial of the use of off-the-shelf, third-party MSCs in severe
steroid-refractory acute GVHD in children. These studies
were based on custom MSC trials performed in Europe.
Laboratory data that MSCs have immunoregulatory capabil-
ities encouraged the clinical use of MSCs for severe GVHD,
resulting in a case report in 2004 of a child treated with
maternal MSCs who had a dramatic response [7]. These cells
have a certain degree of heterogeneity based on how they are
obtained, culture conditions, and so on, so the International
Society for Cellular Therapy proposed minimal criteria for
deﬁning the cells based on plastic adherence, phenotype, and
trilineage multipotency [8]. They express CD73, CD90, and
CD105 but lack CD11b, CD1, CD34, CD45, CD19, CD79a, or
HLA-DR; also, they must differentiate to osteoblasts, adipo-
cytes, and chondroblasts in vitro.
In Europe, MSCs commonly used in GVHD therapy are
mostly locally derived [9]. No phase III data of such MSCs
has been reported. On the other hand, 2 phase III, ran-
domized trials were performed in the United States using a
third-party, off-the-shelf product derived from 7 donors
(remestemcel-L, Prochymal, Osiris Therapeutics, Columbia,
MD). The ﬁrst study used MSCs plus prednisone for pri-
mary therapy of GVHD, and the second trial was for
steroid-resistant GVHD. Some of the data from these
studies were presented at the Tandem meeting in 2010
[10], but neither study has yet been published as a full,
peer-reviewed article.
In a primary therapy trial, the MSC infusion did not ach-
ieve its primary goal, although post hoc analysis of a pediatric
subset appeared to be promising [11]. In a steroid-refractory
trial, overall GVHD responses were essentially identical, but
gut and liver responses seemed a bit more robust. What
accounts for the enthusiasm for this approach in Europe and
in children, while the deﬁnitive studies in adults in the
United States were negative and remain unpublished? A nice
analysis of some of the problems in interpretation of the
differences in these trials was recently published [12]. One
difference may be the MSCs themselves. Despite an accepted
deﬁnition of MSCs, the assumption that MSCs from different
donors prepared in different laboratories with different re-
agents have equal efﬁcacy may not be correct. In European
studies there are limited passages of the cells through cul-
ture. We do not know howmany expansions are undertaken
for the remestemcel-L product, but presumably many. Does
telomere shortening inﬂuence their efﬁcacy? Is there any
evidence of clonal dominance or epigenetic evolution of the
cells? Is there an inﬂuence of cryopreservation on MSC
function in vivo? Can these differences explain the disparity
between European and US results?
The study by Kurtzberg et al. used the same MSCs as the
phase III trial. Were the phase III trials underpowered? If the
results differ between adults and children, it would be
helpful to deﬁne the difference in biology that provides a
plausible explanation. To what extent does residual thymic
function affect the efﬁcacy of MSCs? As we often observe inphase II trials, the heterogeneity of the diagnoses, stem cell
sources, and therapies make some data difﬁcult to assess.
For instance, of the secondary therapies used in this study,
none has proven efﬁcacy in a randomized trial. Moreover,
daclizumab and mycophenolate mofetil have been proven
to be ineffective [1,2] or even detrimental. Thus, patients did
not really fail multiple effective therapies. Second, the time
to MSC therapy from onset of GVHD was a median of
30 days but ranged from 2 to 1639 days. Some of these
patients appear to have an aggressive deﬁnition of failure of
primary therapy, whereas others have late-onset acute
GVHD, which may be different from GVHD occurring in a
more conventional time frame. Finally, the overall response
rate seems quite good, but there are relatively few complete
responders.
Ultimately, we will not be able to deﬁnitively assess the
role of MSC therapy until proper randomized trials are
published. The results of the Prochymal trials need to be
analyzed and published so we can determine their limita-
tions and plan the next set of randomized trials. Perhaps
home-grown MSCs will ultimately be necessary. It makes
little sense to study any GVHD therapy after there is such
severe organ injury that regeneration of the gut mucosa or
biliary system is impossible, but to justify earlier therapy,
we need a reliable product in which we have some conﬁ-
dence or at least equipoise. It would also make sense to
compare MSC therapy with ECP so we can determine
whether either of these therapies should be more widely
used.
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